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Objective: Data regarding the long-term efficacy of carotid artery stenting (CAS) are still scarce. As demonstrated by
several major randomized controlled trials (RCT) comparing the efficacy of carotid endarterectomy (CEA) vs medical
therapy, even after successful carotid revascularization late ipsilateral stroke occurs in 5-13% at 5 years. Therefore, major
concerns also remain about the durability of the CAS procedure in terms of stroke prevention. The purpose of this study
was to review long-term results after carotid stent implantation in a large cohort of patients.
Methods: This retrospective investigation involved 3179 CAS procedures performed at four European carotid high-
volume centers. Echo-duplex scan using modified velocity criteria to recognize in-stent restenosis (ISR) and neurological
examinations of all patients were carried out every 6months after the procedure. Life-table analysis was used to determine
freedom frommortality, stroke-related death, ipsilateral fatal/major stroke, and any ipsilateral stroke. Freedom from ISR
and from reintervention were also reported. The secondary aim was to identify predictive risk factors for neurological
complications and ISR.
Results: At 5 years freedom frommortality, stroke-related death, ipsilateral fatal/major stroke, and any stroke rate were 82%,
93.5%, 93.3%, and 91.9%, respectively. The only predictor for neurological complications was the presence of neurological
symptoms before CAS (hazard ratio 1.38 [CI 1.05, 1.82] P  .02). Freedom from restenosis at 1, 3, and 5 years was,
respectively, 98.4%, 96.1%, and 94%. Uni- and multi-variate analyses showed that stent characteristics (material/design/free-
cell area) were not significantly associated with time to in-stent restenosis or time to reintervention.
Conclusion: Our long-term results in a large cohort of patients validated CAS as a durable procedure for stroke
prevention. The annual rate of neurological complications after CAS was comparable to that of conventional surgery as
demonstrated by large RCTs involving both symptomatic patients (North American Symptomatic Carotid Endarterec-
tomy Trial [NASCET] and European Carotid Surgery Trial [ECST]) and asymptomatic patients (Asymptomatic Carotid
Atherosclerosis Study [ACAS] and Asymptomatic Carotid Surgery Trial [ACST]). (J Vasc Surg 2008;48:1431-41.)In recent years, carotid artery stenting (CAS) has rap-
idly gained recognition worldwide as a possible alternative
to carotid endarterectomy (CEA). Although excellent re-
sults from centers with a high-volume experience seem to
demonstrate that CAS is technically feasible and safe,1 the
few randomized controlled trials (RCTs) conducted so far
have not clarified the equivalence of this technique com-
pared to CEA in terms of early results2-4 in normal-risk
patients. Moreover, these trials did neglect to publish long-
term results after CAS, and only a few nonrandomized
studies have focused their attention on long-term results
with 5 years of follow-up.5-9
As demonstrated by several RCTs comparing the effi-
cacy of CEA vs medical therapy, even after successful ca-
rotid revascularization late ipsilateral stroke occurs in 5.1-
13% at 5 years.10-14 The major concern for long-term
results after CAS is, therefore, that the plaque, which is
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doi:10.1016/j.jvs.2008.07.012completely removed in CEA surgery, is only remodeled and
contained behind the strut of the stent, so that the only
protection against late embolization is the scaffolding of
the emboligenic plaque by means of the stent. Moreover,
long-term patency following CAS can be limited by reste-
nosis due to neointimal hyperplasia or recurrent atheroscle-
rosis, but no data has been reported regarding the influence
of stent type on these endpoints.
The purpose of this analysis is to review long-term
results after carotid stent implantation in a large cohort of
patients. The primary aim was to analyze: a) freedom from
death, stroke-related death, disabling stroke, or any type of
neurological complication, and b) the behavior of different
implanted stents in terms of patency and need for reinter-
vention. The secondary aim was to identify predictive risk
factors for neurological complications, restenosis, and need
for reintervention during the follow-up after CAS.
METHODS
Cohort of patients. The subject of this investigation
was a selected cohort of 3179 consecutive patients who
underwent CAS procedures at four European carotid high-
volume centers during the 8-year period fromMarch 1998
to June 2006.15-17 During the same period, 2672 patients
underwent CEA (45.7%). A constant drop in the number of
CEA procedures and a rapid growth of indication for
CAS18 has been observed during this 8-year period.
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plex ultrasound scan and magnetic resonance angiography,
followed by digital subtraction angiography at the time of
the procedure to confirm whether lesions were appropriate
for treatment (symptomatic lesions 50%, asymptomatic
lesions80%, calculated according to the North American
Symptomatic Carotid Endarterectomy Trial [NASCET]
criteria).10
Study population and risk factor distribution. The
mean age was 72.4  7.9 years, and the study population
included 2130 (67.0%) men. In total, 1317 (41.4%) pa-
tients presented with symptomatic and 1862 (58.6%) with
asymptomatic disease. Current or former nicotine abuse
was confirmed in 1204 (37.9%) patients and arterial hyper-
tension in 2291 (72.1%). Hypercholesterolemia was found
in 2000 (62.9%) patients and history of coronary or periph-
eral artery disease in 1443 (45.1%). The study included 827
(26.0%) diabetic patients. In total, 2945 (92.6%) of the
patients were treated for a de novo lesion and 234 (7.4%)
for restenosis after CEA (n  206) or after CAS (n  28).
Medical treatment. All patients were treated with ace-
tylsalicylic acid (ASA) at a mean dosage of 80-125 mg/day,
associated with clopidogrel or ticlopidine at a mean dosage
of 75mg/day or 500mg/day respectively for at least 3 days
prior to admission. After the procedure, aspirin in combi-
nation with clopidogrel (75 mg/day) or ticlopidine (500
mg/day) was continued for at least 30 days. At the physi-
cian’s discretion, and according to local reimbursement
policies, mono anti-platelet therapy (either aspirin, clopi-
dogrel, or ticlopidine) was to be continued indefinitely.
Procedures. CAS was performed according to each
unit’s existing standards of care, as described previously.19
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Fig 1. Survival curves in the total population (fr
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Patient at risk 3178 309
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Patients lost at follow-up (per year) 0
e. All neurological complication (any stroke  TIA)
Patient at risk 3178 303
Number of events (per year) 1 14
Patients lost at follow-up (per year) 0 0Each center had experience of over 50CAS (before the start
of data collection, the first 50 patients were not included).
Unprotected stenting was performed in 130 (4.1%)
patients: the majority of these cases dated from the period
in which EPDs were not yet widely available. In the remain-
ing 3049 (95.9%) patients, commercially available EPDs
were selected and applied: 2831 (92.9%) distal filters, 192
(6.4%) proximal occlusion, and 26 (0.8%) distal occlusion
devices. Dedicated self-expanding carotid stents were used
in all patients: nitinol stents were used in 1072 (33.7%) and
stainless steel stents in 2107 (66.3%) patients.
Follow-up. Patients were requested to undergo echo-
duplex scan and neurological examinations of all patients
were carried out at 1, 3, 6, and 12 months after the
procedure and then yearly. Patients were instructed to
inform the physician when any new symptoms occurred
after hospital discharge. Exact information about clinical
events was obtained for all patients. Neurologic exam was
performed primarily by the physician who did the echo-
duplex scan. All new neurological events were confirmed by
an independent neurologist and either a brain CT or MRI
was performed if any change in neurological status was
found.
Modified velocity criteria were used to identify in-stent
restenosis (ISR), according to the parameters of Lal, et al,20
(peak systolic velocity [PSV] 210 to 300 cm/s with end-
diastolic velocity less than 120 cm/s, to detect ISR 60% to
79%; PSV greater than 300 cm/s and end-diastolic velocity
greater than 120 cm/s, or internal carotid to common
carotid artery systolic velocity ratio greater than 3.2, for
ISR80% to 99%). ISR was defined as a narrowing of 50%
or more (PSV 175 cm/s).21 Indications for reinterven-
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
from event at 5 year and standard error [SE]).
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symptomatic patients, as documented by echo-duplex scan
and confirmed by intraprocedural angiography (NASCET
criteria).
Stroke classification. Strokes were classified accord-
ing to their probable location (ipsilateral, contralateral) and
their consequences (fatal, disabling, or non-disabling). A
stroke was considered fatal when it caused the death of the
patient, either directly due to brain damage, or indirectly
due to a non-neurological complication.
A disabling stroke was a stroke that was associated with
disability 6 months afterward, with a modified Rankin scale
score of at least 3 (ie, at least moderate disability from the
index stroke, with the need for some help in daily affairs).
A non-disabling stroke was one that after 6 months was
associated with a modified Rankin score of less than 3 (ie, at
most only slight disability from the index stroke, without
the need for assistance in daily affairs).
Aims and statistical analysis. The first aim of this
study was to analyze long-term stroke prevention after CAS
and to evaluate the long-term behavior of the implanted
carotid stents concerning patency rate and need for reinter-
vention.
Neurological complications were reported in terms of
freedom from: overall mortality, stroke-related death, all
ipsilateral neurological complications (transient ischemic
attack [TIA], disabling or non-disabling stroke), and ipsi-
lateral fatal/disabling stroke. The behavior of the im-
planted stent was reported in terms of freedom from ISR
and reintervention.
Our secondary aim was to identify predictive risk fac-
tors for ipsilateral neurological complications and for ISR.
The risk factors indicated by the various investigators as
being potentially predictive of the late neurological event
rate were: age, symptomatic status, male gender, nicotine
abuse, hypertension, hypercholesterolemia, history of cor-
onary or peripheral artery disease, diabetes, and restenosis
after CEA/CAS.
The risk factors related to the stent properties and
indicated as being potentially predictive of ISR and the
necessity for reintervention were: stent material (stainless
steel vs nitinol) and different free-cell area (stents were
subdivided into four subgroups: 2.5 mm2, 2.5-5 mm2,
5-7.5 mm2, and 7.5 mm2).
Analysis of time to the different complications was
based on Kaplan-Meier curves with 95% confidence bands.
Because Kaplan-Meier curves ignore that death from other
Table I. Proportion (in %) in the total population with co
Complication Year 1 Yea
All-cause mortality 2.1 (1.6-2.7) 6 (5
Stroke-related mortality 1.2 (0.8-1.6) 2.4 (1
Fatal/disabling stroke 1.9 (1.4-2.3) 3.2 (2
Any stroke 2.3 (1.7-2.8) 4.2 (3
All neurological complications 4.1 (3.4-4.8) 6.4 (5causes is a “competing risk”, as they assume that patientswho die from other causes still have a risk of stroke-related
death, Kaplan-Meier analysis of all complication events,
except overall mortality, were accommodated using a
“competing risk analysis”.22-24
Risk factors for complication events were detected in
both a univariate and multivariate analysis, using Cox
proportional hazards regression models. Effects were
retained in the model when significant at the 5% signifi-
cance level. In a secondary analysis, stepwise regression
methods involving Akaike’s Information Criterion were
used, allowing for two-way interactions between any pair
of variables. All analyses were conducted in R Version
2.3.0 using the Design package (by Frank Harrell,
Vanderbilt University) for Kaplan-Meier curves, the
Competing Risk package (Bob Gray, Harvard Univer-
sity) for competing risk analysis and the survival package
for Cox proportional hazards modeling.
RESULTS
As previously published,15 the 30-day rates for death,
disabling stroke, non-disabling stroke and TIA were found
to be 0.2, 0.4, 0.7, and 1.5%, respectively. This results in a
cumulative 30-day event rate after CAS of 2.8%.
For long-term analysis, at least 1-year follow-up was
completed for all patients. A total of 133 patients were
lost at different times during the follow-up period. The
mean follow-up period was 961  488 days (range,
365-2863).
During the follow-up period, a total of 202 patients
died, including 68 ipsilateral stroke-related deaths (fatal
strokes) and 134 non-lesion related deaths, of which 7 were
contralateral stroke-related and 127 due to other causes.
The survival curve at 1, 3, and 5 years was, respectively,
97.9%, 90.2%, and 82% (Fig 1, a, Table I).
During the follow-up, 116 ipsilateral strokes (82 dis-
abling and 34 non-disabling strokes), and 11 contralateral
strokes were diagnosed. Only ipsilateral strokes were con-
sidered for the analysis. Freedom from ipsilateral stroke-
related mortality at 1, 3, and 5 years was, respectively,
98.8%, 96.2%, and 93.5% (Fig 1, b, Table I).
Table I summarizes the results at years 1, 2, 3, 4, and 5
for the endpoints studied: all cause mortality, ipsilateral
stroke-related mortality, ipsilateral fatal/disabling stroke,
any stroke, and all ipsilateral neurological complications
(TIA and any stroke). At 5 years, freedom from any ipsilat-
eral stroke was 91.9% (Fig 1, d, Table I).
Annual rates (ie, expected number of events per year
cations in the given period, with 95% confidence interval
Year 3 Year 4 Year 5
) 9.8 (8.3-11) 14 (11-16) 18 (15-21)
) 3.8 (2.8-4.8) 5.2 (3.8-6.7) 6.5 (4.5-8.6)
4.6 (3.5-5.7) 6.4 (4.8-8) 6.7 (5-8.4)
5.6 (4.5-6.7) 7.5 (5.8-9.1) 8.1 (6.3-10)
) 8 (6.8-9.3) 10 (8.5-12) 11 (9-13)mpli
r 2
.1-7.2
.8-3.1
.5-4)
.4-5)per 100 event-free patients) for each complication in the
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show the event-free curves analyzed for symptomatic and
asymptomatic populations.
ISR50% was detected in 88 patients, of which only 8
were symptomatic. Life-table analysis showed freedom
from event at 1, 3, and 5 years of 98.6%, 95.9%, and 93.5%
(Fig 3, Table IV). No stent fracture was observed. Two
asymptomatic cases of stent occlusion were detected at year
2 and 3.5. Reintervention was performed in 64 cases (56
asymptomatic ISR 80%, 8 symptomatic ISR 50%), in-
cluding four stent removals (2 cases of acute CAS throm-
bosis25 and 2 late surgical conversions), and 60 further
endovascular approaches (23 angioplasties, 14 angioplas-
ties followed by stenting, 15 cutting balloon angioplasties,
and 8 cutting balloon angioplasties followed by stenting).
Two patients had recurrence of ISR and were treated with
further cutting balloon angioplasty. Table V reports the
univariate comparison of all categorical risk factors in pa-
tients with and without complications during follow-up. It
shows that the incidence of ipsilateral neurological compli-
cations (of any type) is 38% (95% confidence interval 5%-
82%, P  .02) higher in the symptomatic population than
in the asymptomatic population.
Tables VI and VII show that stent design material
(stainless steel vs nitinol) and free-cell areas are not signifi-
cantly associated with the incidence of in-stent restenosis
and incidence of reintervention.
DISCUSSION
So far, only one RCT26 comparing CEA vs CAS in
high-risk patients has reported data in favor of CAS, while
the recent EVA-3S (Endarterectomy vs Angioplasty and
Stenting in Patients With Symptomatic Severe Carotid
Stenosis)27 and SPACE (Stent-Protected Angioplasty vs
Carotid Endarterectomy)28 RCTs failed to clarify whether
stenting can be considered “equivalent” to CEA in normal-
risk patients. Indications for and the outcome of CAS,
therefore, remain a controversial topic, while no long-term
(5 years) data from any RCTs are currently available. The
3-year results from SAPPHIRE have been recently report-
ed:29 the composite rate of death, stroke, or myocardial
infarction within 30 days or death or ipsilateral stroke
between 31 days and 3 years was 26.2% in the stenting
Table II. Average Annual rates (ie, number of events per
year per 100 event-free patients) for all complications in
the total population, with 95% confidence interval
Complication Annual rate 95% CI
All-cause mortality 3.43 (3-3.9)
Stroke-related mortality 1.31 (1-1.6)
All neurological complications 3.45 (3-3.9)
Any stroke 1.9 (1.7-2.4)
Fatal/disabling stroke 1.70 (1.4-2.1)
In-stent restenosis 1.49 (1.2-1.8)
Reintervention 1.08 (0.8-1.4)group and 30.3% in the endarterectomy group (P  ns).Should the long-term data turn out to be unsatisfac-
tory, the whole debate about indications, optimal tech-
niques, equipment, and early outcomes would be no longer
worthy of discussion.
We have already reported the 30-day outcome after
CAS for this large cohort of patients,15 and we have found
that there is substantial evidence of differences in adverse
event rates according to the stent used. In particular, the
post-procedural complication rates in the symptomatic
population were highest for the open-cell types and in-
creased with a larger free-cell area, while no significant
differences could be established in the asymptomatic pop-
ulation.
The aim of this analysis was to study the durability of
the endovascular procedure in terms of stroke-prevention,
restenosis, and need for reintervention. For the moment,
only a few series of cases with long-term follow-up after
CAS have been reported,6-9,30 and no studies have ana-
lyzed the behavior of the implanted stent over time on the
basis of the different stent materials.
Bergeron, et al,9 reported long-term results in a series
of 221 CAS, with a 96% freedom from stroke rate at 3 years.
In a series of 528 consecutive patients who underwent 604
carotid stenting procedures, Roubin, et al,8 found a 3-year
freedom from all fatal and nonfatal stroke rates of 88 2%,
and 95  2%, respectively, with and without the inclusion
of the 30-day periprocedural period.
To our knowledge, our study is the largest patient
cohort followed over the longest period of time in the
literature that compares long-term stroke prevention and
the influence of stent material. In this respect, in the
absence of long-term results fromRCTs comparing CEA vs
CAS, this data could be compared to data from RCTs
comparing CEA to medical therapy.
In our series, the annual rate of 1.7% (95% CI 1.4-2.1)
for any type of ipsilateral fatal/disabling stroke, as reported
in our total population, seems to be in the same range as
that of post CEA complications reported by large
RCTs.10,12-14 In particular, the any type of stroke or peri-
operative death rate of 6.42% at 5 years reported for asymp-
tomatic patients by the Asymptomatic Carotid Surgery
Trial (ACST)14 or of 5.1% reported by the Asymptomatic
Carotid Atherosclerosis Study (ACAS)13 are close to the
7.4% rate in our asymptomatic population (Table III). In
our symptomatic population, the any ipsilateral stroke rate
at 3 and 5 years were 7% and 9.2% (Table III), which are
clearly comparable with the 8.5% rate of the European
Carotid Surgery Trial (ECST)12 at 3 years, and the 13% rate
of the North American Symptomatic Carotid Endarterec-
tomy Trial (NASCET).10
Moreover, if we take into account the natural history of
the disease in untreated patients from RCTs (risk of stroke
at 5 years of 11% in asymptomatic patients,13 and of 25% in
symptomatic patients),10 our data seem to reveal an im-
proved outcome in both asymptomatic (7.4%, aggregate
risk reduction 32%) and symptomatic CAS patients
(9.2%, aggregate risk reduction 63%).
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that renal insufficiency, male sex, age 70 years, and a
lesion located at the bifurcation were good predictors of
early and late neurologic complications of CAS. In our
study, the only factor to predict late neurological compli-
cations at univariate analysis was the presence of symptoms
before CAS (hazard ratio 1.38 [95% CI 1.05-1.82], P 
.02). To understand the pathophysiology of these late
neurological events remains speculative. However, the high
number of ipsilateral strokes compared to contralateral
strokes, seems to suggest the excluded lesion behind the
stent as the source of emboli, especially if this is symptom-
atic before the treatment.
The durability of CAS is also strictly related to the
incidence of ISR, which continues to be the “Achilles’
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Fig 2. Survival curves in the symptomatic and the asy
standard error [SE]).
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a. All cause mortality
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Number of events (per year)
asymptomatic 0 3
symptomatic 1 3
Patients lost at follow-up (per year) 0
b. Stroke related mortality
Patient at risk
asymptomatic 1861 181
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asymptomatic 1861 182
symptomatic 1317 129
Number of events (per year)
asymptomatic 0 2
symptomatic 1 2
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d. Any stroke
Patient at risk
asymptomatic 1861 182
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Patient at risk
asymptomatic 1861 178
symptomatic 1317 124
Number of events (per year)
asymptomatic 0 6
symptomatic 1 7Patients lost at follow-up (per year) 0 0heel” of any catheter intervention. Despite several thou-
sand CAS procedures being reported in the literature, the
real incidence of ISR after CAS is unclear, with a range from
5%31,32 to 21%.33,34
This variability is essentially related to the different US
velocity criteria used to define ISR. It is now evident that
CAS induces permanent alterations to the physiological
flow behavior, in terms of compliance mismatch between
the native carotid artery and the stented segment, positive
arterial remodeling (stent expansion), and enhanced stiff-
ness of the stent-arterial wall. These alterations lead to an
increase in velocity also in the absence of ISR.
Using modified velocity criteria, as defined previously,
we found an acceptable annual ISR 50% rate of 1.49%,
(95% CI 1.19-1.83), and a cumulative rate at 5 years of 6%
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
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rate of ISR 80% of 6.4% at 60 months reported by Lal,
et al,20 using the same parameters.
ISR was correlated with neurologic events only in 8 out
of 88 cases. The stroke rate in this group of patients
(cumulative rate 9.1%) was only slightly superior to patients
without ISR, so the benefit of reintervention in reducing
stroke risk might be questionable. However, no studies in
Fig 3. Restenosis and reintervention in the total popula
0 1 2
a. Restenosis (50%)
Patient at risk 3178 3129 2740
Number of events (per year) 0 49 14
Patients lost at follow-up (per year) 0 0 22
b. Reintervention
Patient at risk 3178 3140 2746
Number of events (per year) 0 38 8
Patients lost at follow-up (per year) 0 0 22
Table III. Proportion (in %) in the symptomatic and asym
with 95% confidence interval
Complication Year 1 Year
Symptomatic population
All-cause mortality 2.5 (1.8-3.6) 7.6 (6-9.
Stroke-related mortality 1.6 (0.9-2.4) 3 (1.9-
Fatal/disabling stroke 2.6 (1.7-3.5) 4.1 (2.8-
Any stroke 3 (2.1-4) 5.5 (4.1-
All neurological complications 5.1 (3.9-6.3) 7.9 (6.3-
Asymptomatic population
All-cause mortality 1.8 (2.2-3.5) 4.9 (3.8-
Stroke-related mortality 0.9 (0.5-1.3) 2 (1.2-
Fatal/disabling stroke 1.3 (0.8-1.8) 2.6 (1.7-
Any stroke 1.7 (1.1-2.3) 3.3 (2.3-
All neurological complications 3.3 (2.5-4.2) 5.4 (4.2-literature report stroke risk in patients with untreated ISR,so it seems acceptable to treat ISR 80% in symptomatic
and 50% in asymptomatic patients.
We also studied the influence of different stent proper-
ties (stent material: stainless steel vs nitinol; free-cell area:
2.5 mm2, 2.5-5 mm2, 5-7.5 mm2, and 7.5 mm2) on
the incidence of ISR and of reintervention. Although we
have already demonstrated in this cohort of patients that
there is substantial evidence for differences in early adverse
(freedom from event at 5 year and standard error [SE]).
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9.3 (7.4-11.7) 13.3 (10.5-16.7) 18.7 (14.8-23.6)
3.3 (2-4.5) 4.8 (2.8-6.8) 6.1 (3.5-8.8)
3.9 (2.5-5.2) 6.1 (3.9-8.2) 6.6 (4.2-9)
4.5 (3.1-5.9) 6.8 (4.6-9.1) 7.4 (5-9.8)
7 (5.4-8.6) 10.1 (7.5-12.7) 10.6 (7.9-13.4)tion
1
1ptom
2
6)
4.1)
5.3)
6.9)
9.6)
6.3)
2.8)
3.5)
4.3)event rates between different cell designs,15 uni- and multi-
2.3)
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characteristics (material/design/free-cell area) were not
significantly associated with ISR or reintervention. Consid-
ering the wide confidex intervals, these results lead only to
a hypothesis: the scaffolding properties of the stent play an
important role in the early postoperative period, but this
Table IV. Proportion (in %) of patients in the total popul
given period, with 95% confidence interval
Complication Year 1 Year
In-stent restenosis 50% 1.6 (1.2-2.1) 2.5 (1.9-
Reintervention 1.3 (0.9-1.7) 1.8 (1.2-
Table V. Univariate analysis: hazard ratios for all
neurological complication in the total population
Risk factor
Hazard
ratios
95% confidence
interval P
Gender (male) 0.92 (0.7-1.2) .59
Octogenarian and older 1.02 (0.7-1.5) .91
Symptoms 1.38 (1.1-1.8) .02
Polivascular disease 1.03 (0.8-1.4) .83
Hypertension 1.03 (0.7-1.4) .87
Diabetes 1.17 (0.9-1.6) .32
Hypercholesterolemia 0.99 (0.7-1.3) .94
Restenotic lesion 0.87 (0.5-1.4) .57
Nicotine 0.95 (0.7-1.3) .73
Table VI. Hazard ratios for in-stent restenosis in the
total population
Risk factor
Hazard
ratios
95% confidence
interval P
Stent design 1.28 (0.8-2.1) .35
Free cell area (mm2) .64*
2.5 1
2.5-5 0.33 (0.1-2.3) .27
5-7.5 0.80 (0.4-1.7) .58
7.5 0.87 (0.5-1.7) .69
*P value of global test for association between free cell area and time to
in-stent restenosis.
Table VII. Hazard ratios for reintervention in the total
population
Risk factor
Hazard
ratios
95% confidence
interval P
Stent design 0.98 (0.6-1.7) .95
Free cell area (mm2) .86*
2.5 1
2.5-5 0.48 (0.1-3.5) .47
5-7.5 1.00 (0.4-2.3) .99
7.5 1.16 (0.6-2.3) .68
*P value of global test for association between free cell area and time to
reintervention.ends when the intravascular stent endothelialization pro-cess is completed (generally after 30 days), and has no
influence on the long-term patency rate.
CONCLUSION
Long-term results in a large cohort of patients validate
CAS as a durable procedure for stroke prevention. The ISR
rate appears to be acceptable, and the need for reinterven-
tion is low and unrelated to the characteristics of the device.
The annual rate of neurological complications after CAS is
comparable to that of conventional surgery, as demon-
strated by large RCTs both for symptomatic patients
(NASCET and ECST) and asymptomatic patients (ACAS
and ACST).
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Dr Richard Cambria (Boston, Mass). I would like to open
with one question about the follow-up on the issue of restenosis.
You expressed your data in actuarial methods. Can you tell us how
many patients actually completed the 5-years of follow-up in terms
of assessing the risk of restenosis?
Dr de Donato. We have a mean follow-up of 3 years, but
patientswhohave completed the 5-year follow-up are about 550.The
number of patients at risk were shown under each curve onmy slides.
Dr Wesley Moore (Los Angeles, Calif). I was following your
presentation until you got to the point where you compared the
results of carotid artery stenting with the surgical results from
NASCET and ACAS. Remember that those surgical results are
now 15 to 20-years-old. It is very clear from a number of presen-
tations here and from current publications that the results of
carotid endarterectomy have improved over time. Therefore, it is
unreasonable to compare the results of a contemporary angioplastyfar better if you looked at the current national discharge data study
that has shown contemporary results of carotid endarterectomy.
Mortality and stroke morbidity have dropped with carotid endar-
terectomy over time. If you were to use current carotid endarter-
ectomy data, you would find that the current results of stent/
angioplasty come in second best.
Dr de Donato. Yes, I totally agree with you. But I think that up
to now the old randomized control trials have been of value as a
benchmark to be compared to, whilewe are still waiting for long-term
results from randomized controlled trials comparing carotid artery
stenting and carotid endarterectomy. The aimof this presentationwas
to show that long-term results of CAS are comparable to CEA.
Dr John Ricotta (Stony Brook, NY). The previous paper
showed excellent results in a very broad study that involved multiple
centers and multiple surgeons. You have tremendous results from
three centers, each of which performed at least an average of 1000
carotid stents. How are we going to deal with the issue of volume-
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Volume 48, Number 6 de Donato et al 1441related results? Should we all fly to Europe when we need our carotid
stent? Andwhat’s going to happen when this methodology is dissem-
inated widely? Do you think it should be disseminated widely, or do
you think it should be done only in very selected centers?
Dr de Donato. Yes, this is true. We think that the learning
curve is very important. We think that the volume experience is
another key factor for successful results. Actually, there were four
centers. But anyway, all four centers are classified in our opinion as
high-volume centers, that means at least they treat more than 100
or 150 CAS procedures every year. So we think that the volume
and patient selection are important to reach the right result.
Dr Jacob Schneiderman (Ramat Gan, Israel). Beyond your
impressive long-term results, aren’t you concerned about the
potential of premature dementia in patients undergoing CAS,
taking into consideration the numerous published data regarding
subclinical cerebral ischemic events, as demonstrated by diffusion
weighted MRI after CAS?
Dr de Donato. I think that we don’t have this data about
dementia. And we have only data about disabling or non-disabling
stroke. We don’t have this data, I’m sorry.Dr Christos Liapis (Athens, Greece). Was neurological ex-
amination part of the protocol for all patients or was a neurologist
called after a neurological event?
Dr deDonato.No, absolutely. To be honest, our patients had
an independent neurologist follow-up only in case of symptoms.
During the normal follow-up, it was the physician that performed
the ultrasound scan who also performed the neurological exami-
nation.
DrAmyReed (Cincinnati, Ohio). I just had a question on the
follow-up. Do you have any information on how long clopidogrel,
or Plavix, was used postprocedure in these patients?
Dr de Donato. Actually, this is a difficult point to explain,
because we have different local reimbursement policies. So for
example, in Italy, the patients have to pay for this drug. Our
medical protocol involves double antiplatelet therapy for at least 1
month after the procedure, and then only one anti-aggregation
drug with either aspirin, ticlopidine, or clopidogrel. But I think
that only about 25% of our patients received Plavix for a long
period of time.
